Real Name: William Konarzewski
Occupation: Consultant
Interests: Asian Markets, Emerging Markets, Funds, Property, Stocks, US Market
Location: Colchester UK
About Me:
I'm a semi-retired doctor managing a modest share portfolio for my wife and myself since December 2015. Our prime objective is predictable income. Our portfolio is well diversified (too well diversified some might say) with about 50% in funds and 50% in equities. My target is 4% income and enough capital growth to cover inflation. On the whole I invest in large companies with respectable fundamentals and dividend yields of >4%. (Yes I know such companies are intensely boring but they help me sleep well at nights.) Until last October (2018) I had achieved a 10% return (growth plus income) but now my return stands at about 6%.
Spread betting is hobby. I lose money at it (not a lot I hasten to add) but it's taught me about short term market movement and short term price volatility. I've seen 'sucker stock' double in value and good companies do the opposite. If I've learnt one thing, it's that I don't have the qualities needed to be a successful trader.
Apart from UK companies, I invest in US stocks (large companies like Apple, Microsoft, Google, McDonalds, Johnson and Johnson etc), and I hold funds that specialise in equities based in the USA, India and emerging markets
I am an avid reader and spend much of my spare time reading the writings of the great investors like Benjamin Graham, Jess Livermore, Warren Buffett and Peter Lynch. The whole psychology of the stock market fascinates me and I am trying to work out how to use 'reflexivity' - as described by George Soros - to time my buying and selling more effectively.
My novel entitled 'Lion's Breakfast' is a dystopian fiction set in 2050 at a time when there is no funding for pensions or healthcare for the elderly. (This will of course happen - at present we have 4 tax payers supporting each elderly citizen - in 2050 we shall have two tax payers supporting each elderly citizen. I base this on government figures and not my own speculation. We're all living too long!) The book is available on Amazon (Kindle & paperback format) and self-published as I could not persuade any publishers to take it on. Whilst I claim no great merit as a writer - although I do hold an MA in Creative Writing - I believe the whole issue of how a country deals with its aging population is of vital interest to everyone who expects to grow old. It is something most of us prefer not to think about, rather like climate change, unsustainable national debt and the next global recession.
...won't we all end up just buying " Super Stocks"?A reasonable question, Terry. As Ben Hobson pointed out, some 'Super Stocks' did badly (not so long ago Plus500 (LON:PLUS) was a Super Stock until 'typos' were found in its financial statements) and some 'Sucker Stocks' did quite well. My feeling is that the StockRank Styles are just a starting point for our stock picking (like…
I wonder what is his process, can anybody spot the common denominators ?Yes. There's nothing random about his approach - otherwise he wouldn't have drifted away from his bench mark. And all would have been fine, and his reputation would be intact.I can pick out two investing traits.One is his liking for long shots such as Purple Bricks and Allied Minds (or Sucker Stock as…
I'd wonder if one took some darts and threw them at the share price pages of the FT whether one could pick more promising companies to invest in....Without doubt Andrea. Burton Malkiel in 'Random Walk down Wall Street' demonstrated that a dart throwing chimp (i.e. a tracker fund) could outperform 75% of active fund managers. In Mr Woodford's case a passive tracker fund (or a…
Thanks for link to Nicky Morgan's letter. I wasn't aware, previously, of the Guernsey based TISE (The International Stock Exchange) but it seems to be an exchange that lists securities that can't be listed anywhere else. In response to press articles it suspended three of Woodford's investments. But one has to ask how those securities (presumably including those discussed in this thread - Benevolent AI…
A couple of announcements from Benevolent AIThe company’s advanced technology has been shown to outperform human scientists in understanding the cause of disease and is capable of quickly generating drug candidates at scale. The technology is also able to decipher the molecular process of disease and link these disease signatures within patients to ensure that the best drug candidate is given to the best patient…
